LinkedIn Icon Twitter Icon
Dates TBC (March 2019) | Boston, MA

Day One
Tuesday, March 20 2018

Day Two
Wednesday, March 21 2018

08.55
Chair’s Opening Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

09.00
Keynote: Investigating Crucial Factors That Determine the Success of Immune Checkpoint Combinations

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

Synopsis

  • Understanding the importance of sequencing and timing in the administration of combination therapies to maximize efficacy
  • Investigating the most effective approaches to identify truly translational biomarkers to identify patients for checkpoint monotherapy and combination trials
  • Appreciating the true potential of immuno-oncology: what does the future hold for the field and how can we work most effectively to realise this potential

09.30
Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

Synopsis

  • Assessing the relative contributions of the molecule, patient population and endpoint selection to final result
  • Discussing the ways in which recent clinical results have impacted the field and how priorities and practices will change in the near future as a result
  • How will the recent CAR-T approval impact on the use of checkpoint modulators?
  • Understanding the latest monotherapy data and how this will impact the field

10.30
Morning Refreshments & Networking

14.00
Afternoon Refreshments & Networking

Establishing Effective Immuno-Oncology Strategies to Maximize the Efficacy of Established and Novel Checkpoint Pathways

14.30
Enhancing Anti-Tumor Activity with M7824, a Novel Bifunctional Fusion Protein Targeting PD-L1 and TGF-β

  • Yan Lan Senior Director, Translational Immunology, EMD Serono

Synopsis

  • Rationale behind simultaneously targeting PD-L1 and TGF-β using a bifunctional immunotherapeutic
  • Enhanced antitumor efficacy and unique immunophenotypic signature of M7824 in preclinical models
  • M7824 as a combination partner

15.00
Targeting the CD47 “Do Not Eat” Signal With TTI-621 (SIRPa-IgG1 Fc)

Synopsis

  • Understanding the rationale behind targeting CD47
  • Presenting data from clinical studies of the CD47 blocking agent TTI-621 (SIRPa-IgG1 Fc)
  • Discussing combination opportunities involving CD47 blockade

15.30
Chair’s Closing Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center